Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit

Journal of Virological Methods

Volumn 171, Issue 1, 2011, Pages 272-279

  Hu, Bo ^a,b   Li, Chang ^b   Lu, Huijun ^b   Zhu, Zhanbo ^a,b,c   Du, Shouwen ^a,b   Ye, Ming ^b   Tan, Lei ^a,b   Ren, Dayong ^a,b   Han, Jiali ^b   Kan, Shifu ^a,b   Wang, Jing ^a,b   Jin, Ningyi ^b  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

Author keywords

Bacillus subtilis; Foot and mouth disease virus; Immune response; Oral vaccine

Indexed keywords

CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACILLUS SUBTILIS; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GUINEA PIG; HUMORAL IMMUNITY; INFECTION PREVENTION; INTESTINE LAVAGE; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTECTION; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASIA; BACILLUS SUBTILIS; CHOLERA TOXIN; DRUG CARRIERS; EPITOPES; FEMALE; FOOT-AND-MOUTH DISEASE VIRUS; GASTROINTESTINAL TRACT; GENETIC VECTORS; GUINEA PIGS; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

ANIMALIA; BACILLUS SUBTILIS; CAVIA; FOOT-AND-MOUTH DISEASE VIRUS; FOOT-AND-MOUTH DISEASE VIRUS - TYPE ASIA 1; MUS;

EID: 78650530935     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.11.023     Document Type: Article

References (40)

1. Albu D.I., Jones-Trower A., Woron A.M., Stellrecht K., Broder C.C., Metzger D.W. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J. Virol. 2003, 77:5589-5597.
2. Alexandersen S., Kitching R.P., Mansley L.M., Donaldson A.I. Clinical and laboratory investigations of five outbreaks of foot-and-mouth disease during the 2001 epidemic in the United Kingdom. Vet. Rec. 2003, 152:489-496.
3. Alexandersen S., Mowat N. Foot-and-mouth disease: host range and pathogenesis. Curr. Top. Microbiol. Immunol. 2005, 288:9-42.
4. Alexandersen S., Zhang Z., Donaldson A.I., Garland A.J. The pathogenesis and diagnosis of foot-and-mouth disease. J. Comp. Pathol. 2003, 129:1-36.
5. Bittle J.L., Houghten R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A., Rowlands D.J., Brown F. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982, 298:30-33.
6. Boyaka P.N., Ohmura M., Fujihashi K., Koga T., Yamamoto M., Kweon M.N., Takeda Y., Jackson R.J., Kiyono H., Yuki Y., McGhee J.R. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J. Immunol. 2003, 170:454-462.
7. Ciabattini A., Parigi R., Isticato R., Oggioni M.R., Pozzi G. Oral priming of mice by recombinant spores of Bacillus subtilis. Vaccine 2004, 22:4139-4143.
8. Collen T., Pullen L., Doel T.R. T cell-dependent induction of antibody against the foot-and-mouth disease virus in a mouse model. J. Gen. Virol. 1989, 70(Pt 2):395-403.
9. Crowther J.R., Farias S., Carpenter W.C., Samuel A.R. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J. Gen. Virol. 1993, 74(Pt 8):1547-1553.
10. Donaldson A.I., Gibson C.F., Oliver R., Hamblin C., Kitching R.P. Infection of cattle by airborne foot-and-mouth disease virus: minimal doses with O1 and SAT 2 strains. Res. Vet. Sci. 1987, 43:339-346.
11. Driks A. Bacillus subtilis spore coat. Microbiol. Mol. Biol. Rev. 1999, 63:1-20.
12. Duc le H., Hong H.A., Atkins H.S., Flick-Smith H.C., Durrani Z., Rijpkema S., Titball R.W., Cutting S.M. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 2007, 25:346-355.
13. Duc le H., Hong H.A., Cutting S.M. Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery. Vaccine 2003, 21:4215-4224.
14. Duc le H., Hong H.A., Fairweather N., Ricca E., Cutting S.M. Bacterial spores as vaccine vehicles. Infect. Immun. 2003, 71:2810-2818.
15. Francis M.J., Hastings G.Z., Syred A.D., McGinn B., Brown F., Rowlands D.J. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature 1987, 330:168-170.
16. Fu L.L., Li W.F., Du H.H., Dai W., Xu Z.R. Oral vaccination with envelope protein VP28 against white spot syndrome virus in Procambarus clarkii using Bacillus subtilis as delivery vehicles. Lett. Appl. Microbiol. 2008, 46:581-586.
17. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17:465-493.
18. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(Suppl. 2):S89-S95.
19. Kanobana K., Koets A., Kooyman F.N., Bakker N., Ploeger H.W., Vervelde L. B cells and antibody response in calves primary-infected or re-infected with Cooperia oncophora: influence of priming dose and host responder types. Int. J. Parasitol. 2003, 33:1487-1502.
20. Kanobana K., Ploeger H.W., Vervelde L. Immune expulsion of the trichostrongylid Cooperia oncophora is associated with increased eosinophilia and mucosal IgA. Int. J. Parasitol. 2002, 32:1389-1398.
21. Mason P.W., Grubman M.J., Baxt B. Molecular basis of pathogenesis of FMDV. Virus Res. 2003, 91:9-32.
22. Mason P.W., Piccone M.E., McKenna T.S., Chinsangaram J., Grubman M.J. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology 1997, 227:96-102.
23. Mauriello E.M., Cangiano G., Maurano F., Saggese V., De Felice M., Rossi M., Ricca E. Germination-independent induction of cellular immune response by Bacillus subtilis spores displaying the C fragment of the tetanus toxin. Vaccine 2007, 25:788-793.
24. Mauriello E.M., Duc le H., Isticato R., Cangiano G., Hong H.A., De Felice M., Ricca E., Cutting S.M. Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Vaccine 2004, 22:1177-1187.
25. Mingxiao M., Ningyi J., Juan L.H., Min Z., Guoshun S., Guangze Z., Huijun L., Xiaowei H., Minglan J., Xu L., Haili M., Yue J., Gefen Y., Kuoshi J. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18. Antiviral Res. 2007, 76:59-67.
26. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002, 20:1631-1639.
27. Muller N., von Allmen N. Recent insights into the mucosal reactions associated with Giardia lamblia infections. Int. J. Parasitol. 2005, 35:1339-1347.
28. Nicholson W.L., Munakata N., Horneck G., Melosh H.J., Setlow P. Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol. Mol. Biol. Rev. 2000, 64:548-572.
29. O'Hagan D.T., Ott G.S., Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 1997, 3:69-75.
30. Oggioni M.R., Ciabattini A., Cuppone A.M., Pozzi G. Bacillus spores for vaccine delivery. Vaccine 2003, 21(Suppl. 2):S96-S101.
31. Paccez J.D., Luiz W.B., Sbrogio-Almeida M.E., Ferreira R.C., Schumann W., Ferreira L.C. Stable episomal expression system under control of a stress inducible promoter enhances the immunogenicity of Bacillus subtilis as a vector for antigen delivery. Vaccine 2006, 24:2935-2943.
32. Paccez J.D., Nguyen H.D., Luiz W.B., Ferreira R.C., Sbrogio-Almeida M.E., Schuman W., Ferreira L.C. Evaluation of different promoter sequences and antigen sorting signals on the immunogenicity of Bacillus subtilis vaccine vehicles. Vaccine 2007, 25:4671-4680.
33. Sanz-Parra A., Blasco R., Sobrino F., Ley V. Analysis of the B and T cell response in guinea pigs induced with recombinant vaccinia expressing foot-and-mouth disease virus structural proteins. Arch. Virol. 1998, 143:389-398.
34. Sobrino F., Saiz M., Jimenez-Clavero M.A., Nunez J.I., Rosas M.F., Baranowski E., Ley V. Foot-and-mouth disease virus: a long known virus, but a current threat. Vet. Res. 2001, 32:1-30.
35. Song H., Zhou L., Fang W., Li Y., Wang X., Fang H., Li X., Wu M., Qiu B. High-level expression of codon optimized foot-and-mouth disease virus complex epitopes and cholera toxin B subunit chimera in Hansenula polymorpha. Biochem. Biophys. Res. Commun. 2004, 315:235-239.
36. Taboga O., Tami C., Carrillo E., Núñez J.I., Rodríguez A., Saíz J.C., Blanco E., Valero M.L., Roig X., Camarero J.A., Andreu D., Mateu M.G., Giralt E., Domingo E., Sobrino F., Palma E.L. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 1997, 71:2606-2614.
37. Tseng D.Y., Ho P.L., Huang S.Y., Cheng S.C., Shiu Y.L., Chiu C.S., Liu C.H. Enhancement of immunity and disease resistance in the white shrimp, Litopenaeus vannamei, by the probiotic, Bacillus subtilis E20. Fish Shellfish Immunol. 2009, 26:339-344.
38. Zhang X.Z., Cui Z.L., Hong Q., Li S.P. High-level expression and secretion of methyl parathion hydrolase in Bacillus subtilis WB800. Appl. Environ. Microbiol. 2005, 71:4101-4103.
39. Zheng M., Jin N., Zhang H., Jin M., Lu H., Ma M., Li C., Yin G., Wang R., Liu Q. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. J. Virol. Methods 2006, 136:230-237.
40. Zhou Z., Xia H., Hu X., Huang Y., Li Y., Li L., Ma C., Chen X., Hu F., Xu J., Lu F., Wu Z., Yu X. Oral administration of a Bacillus subtilis spore-based vaccine expressing Clonorchis sinensis tegumental protein 22.3 kDa confers protection against Clonorchis sinensis. Vaccine 2008, 26:1817-1825.